^(131)I-Hepama-1单克隆抗体导向治疗肝癌的初步观察

Clinical Study of Monoclonal Antibody in Targeting Therapy of Advanced Liver Cancer

采用１３１Ｉ－Ｈｅｐａｍａ－１单克隆抗体，经股动脉插管至肝动脉或皮下药盒注入肝动脉，治疗２２例不能手术之晚期肝癌患者。结果显示９０％患者卡氏评分上升，多数患者癌性症状减轻，生活质量提高，ＣＲ＋ＰＲ＋ＭＲ率为７２．７％（１６／２２），１年生存率３６．４％（８／２２）。并使部分不能切除之巨大肝癌变为可手术的小肝癌，二期切除率３１．８％（７／２２），经二期切除的患者，１年生存率提高到７１％。认为本方法作为肝癌综合治疗方法之一，疗效肯定，安全，副作用轻。

Twenty-two patients with advanced liver cancer were treated with I 131 Hepama 1 monoclonal antibody into hepatic artery either via catheterizing femoral artery or built in chamber. The results showed that in 90% of the patients the Karnofsky score of performance status was elevated after treatment.Improvement of symptoms and signs were observed in most of the treated patients in addition to improvement of quality of life. The overall rate of CR+PR+MR was 72.7%,and the 1 year survival rate was 36.4%.Some huge unresectable liver tumors shrank and became resectable and, the secondary operation rate was 31.8%. The 1 year survival rate of these patients was raised to 71%. It is shown that the targeting therapy with I 131 Hepama 1 monoclonal antibody provided high effectiveness,less side effects and warrants futher study.